Login to Your Account



Genzyme's Buyout Of SangStat: Ripening Treasure In Polyclonals?

By Randall Osborne


Monday, August 11, 2003

Last week's news of a planned $600 million cash buyout of SangStat Medical Corp. by Genzyme Corp. made headlines for its obvious virtues on both sides - but down the road an even bigger boon might be coming for the merged pair. It's a benefit that inspired phrases such as "medical revolution" and "whole new world" from Bill Martin, director of corporate communications for SangStat.

To continue reading subscribe now to BioWorld Insight

Learn More about BioWorld Insight

Already a subscriber? Sign In or Buy now to activate your subscription